COMP <GO>
TELO vs ACRV // REVENUE GROWTH (YOY)
Telomir Pharmaceuticals Inc. (NASDAQ) VS. Acrivon Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TELO 0
— ACRV 2
■ METRIC PARITY
LAST: $0.92 (-2.15%) • MKT CAP: $67.4M
revenue-growth
—
LAST: $1.61 (-3.01%) • MKT CAP: $69.0M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TELO VS. ACRV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TELO | ACRV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.19% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.4 | 36.2 | -8.80 | ACRV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $67.4M | $69.0M | -$1.6M | ACRV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TELO REV | ACRV REV | TELO GROSS % | ACRV GROSS % | TELO FCF | ACRV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.1M | $235.5M | — | — | -$3.7M | -$65.3M |
| FY 2024 | $556.1K | $249.8M | — | — | -$5.1M | -$68.4M |
| FY 2023 | $58.8M | $187.9M | — | — | -$3.9M | -$42.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TELO // BETA —
ACRV // BETA —